CN106117580A - 一种用于滤除白细胞的滤膜改性剂及其改性方法 - Google Patents
一种用于滤除白细胞的滤膜改性剂及其改性方法 Download PDFInfo
- Publication number
- CN106117580A CN106117580A CN201610471055.XA CN201610471055A CN106117580A CN 106117580 A CN106117580 A CN 106117580A CN 201610471055 A CN201610471055 A CN 201610471055A CN 106117580 A CN106117580 A CN 106117580A
- Authority
- CN
- China
- Prior art keywords
- filter membrane
- modifying agent
- membrane modifying
- acrylate copolymer
- fibroin albumen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000012528 membrane Substances 0.000 title claims abstract description 101
- 210000000265 leukocyte Anatomy 0.000 title claims abstract description 50
- 238000000034 method Methods 0.000 title claims abstract description 16
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 64
- 108010022355 Fibroins Proteins 0.000 claims abstract description 40
- 229920001577 copolymer Polymers 0.000 claims abstract description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 28
- 239000003607 modifier Substances 0.000 claims abstract description 21
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 21
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 21
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims abstract description 21
- 239000000178 monomer Substances 0.000 claims abstract description 9
- JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 claims abstract description 4
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical group COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000000243 solution Substances 0.000 claims description 18
- 238000006243 chemical reaction Methods 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 15
- -1 polybutylene terephthalate Polymers 0.000 claims description 14
- 229920001707 polybutylene terephthalate Polymers 0.000 claims description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 12
- 239000000835 fiber Substances 0.000 claims description 10
- 230000002209 hydrophobic effect Effects 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 239000007864 aqueous solution Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 239000011347 resin Substances 0.000 claims description 8
- 229920005989 resin Polymers 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- 239000012467 final product Substances 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 230000005855 radiation Effects 0.000 claims description 6
- 239000000376 reactant Substances 0.000 claims description 5
- 230000033228 biological regulation Effects 0.000 claims description 4
- 239000003999 initiator Substances 0.000 claims description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 3
- 239000008351 acetate buffer Substances 0.000 claims description 3
- 239000004202 carbamide Substances 0.000 claims description 3
- 239000008367 deionised water Substances 0.000 claims description 3
- 229910021641 deionized water Inorganic materials 0.000 claims description 3
- 238000006073 displacement reaction Methods 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 102000035118 modified proteins Human genes 0.000 claims description 3
- 108091005573 modified proteins Proteins 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 125000002252 acyl group Chemical group 0.000 claims 2
- 238000005576 amination reaction Methods 0.000 claims 2
- 238000005034 decoration Methods 0.000 claims 1
- 238000007598 dipping method Methods 0.000 claims 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 claims 1
- OJURWUUOVGOHJZ-UHFFFAOYSA-N methyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-(2-methoxy-2-oxoethyl)amino]ethyl]amino]acetate Chemical compound C=1C=CC=C(OC(C)=O)C=1CN(CC(=O)OC)CCN(CC(=O)OC)CC1=CC=CC=C1OC(C)=O OJURWUUOVGOHJZ-UHFFFAOYSA-N 0.000 claims 1
- 238000012545 processing Methods 0.000 abstract description 4
- 230000008595 infiltration Effects 0.000 abstract description 2
- 238000001764 infiltration Methods 0.000 abstract description 2
- 239000002798 polar solvent Substances 0.000 abstract description 2
- 239000012633 leachable Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 26
- 239000008280 blood Substances 0.000 description 26
- 238000001914 filtration Methods 0.000 description 25
- 230000000052 comparative effect Effects 0.000 description 21
- 239000000463 material Substances 0.000 description 12
- 230000004048 modification Effects 0.000 description 11
- 238000012986 modification Methods 0.000 description 11
- 238000012360 testing method Methods 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 8
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000011049 filling Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 description 4
- 238000004088 simulation Methods 0.000 description 4
- 229920006243 acrylic copolymer Polymers 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 229920002635 polyurethane Polymers 0.000 description 3
- 239000004814 polyurethane Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 2
- 230000000702 anti-platelet effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000010118 platelet activation Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 208000003441 Transfusion reaction Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000012223 aqueous fraction Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 239000003914 blood derivative Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 229920001688 coating polymer Polymers 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000004388 gamma ray sterilization Methods 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 210000003677 hemocyte Anatomy 0.000 description 1
- 229940000351 hemocyte Drugs 0.000 description 1
- 238000002615 hemofiltration Methods 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- DCPMPXBYPZGNDC-UHFFFAOYSA-N hydron;methanediimine;chloride Chemical compound Cl.N=C=N DCPMPXBYPZGNDC-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- IWVKTOUOPHGZRX-UHFFFAOYSA-N methyl 2-methylprop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.COC(=O)C(C)=C IWVKTOUOPHGZRX-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- 210000001792 thromboblast Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J7/00—Chemical treatment or coating of shaped articles made of macromolecular substances
- C08J7/04—Coating
- C08J7/0427—Coating with only one layer of a composition containing a polymer binder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/02—Blood transfusion apparatus
- A61M1/0259—Apparatus for treatment of blood or blood constituents not otherwise provided for
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D39/00—Filtering material for liquid or gaseous fluids
- B01D39/08—Filter cloth, i.e. woven, knitted or interlaced material
- B01D39/083—Filter cloth, i.e. woven, knitted or interlaced material of organic material
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
- C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
- C08F220/10—Esters
- C08F220/34—Esters containing nitrogen, e.g. N,N-dimethylaminoethyl (meth)acrylate
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D133/00—Coating compositions based on homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides, or nitriles thereof; Coating compositions based on derivatives of such polymers
- C09D133/04—Homopolymers or copolymers of esters
- C09D133/14—Homopolymers or copolymers of esters of esters containing halogen, nitrogen, sulfur or oxygen atoms in addition to the carboxy oxygen
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D139/00—Coating compositions based on homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen; Coating compositions based on derivatives of such polymers
- C09D139/04—Homopolymers or copolymers of monomers containing heterocyclic rings having nitrogen as ring member
- C09D139/06—Homopolymers or copolymers of N-vinyl-pyrrolidones
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D189/00—Coating compositions based on proteins; Coating compositions based on derivatives thereof
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2239/00—Aspects relating to filtering material for liquid or gaseous fluids
- B01D2239/04—Additives and treatments of the filtering material
- B01D2239/0414—Surface modifiers, e.g. comprising ion exchange groups
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2239/00—Aspects relating to filtering material for liquid or gaseous fluids
- B01D2239/04—Additives and treatments of the filtering material
- B01D2239/0471—Surface coating material
- B01D2239/0492—Surface coating material on fibres
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2239/00—Aspects relating to filtering material for liquid or gaseous fluids
- B01D2239/06—Filter cloth, e.g. knitted, woven non-woven; self-supported material
- B01D2239/0604—Arrangement of the fibres in the filtering material
- B01D2239/0618—Non-woven
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2367/00—Characterised by the use of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Derivatives of such polymers
- C08J2367/02—Polyesters derived from dicarboxylic acids and dihydroxy compounds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2433/00—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides, or nitriles thereof; Derivatives of such polymers
- C08J2433/04—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides, or nitriles thereof; Derivatives of such polymers esters
- C08J2433/14—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides, or nitriles thereof; Derivatives of such polymers esters of esters containing halogen, nitrogen, sulfur, or oxygen atoms in addition to the carboxy oxygen
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2439/00—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen; Derivatives of such polymers
- C08J2439/04—Homopolymers or copolymers of monomers containing heterocyclic rings having nitrogen as ring member
- C08J2439/06—Homopolymers or copolymers of N-vinyl-pyrrolidones
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2489/00—Characterised by the use of proteins; Derivatives thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Materials Engineering (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Textile Engineering (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- External Artificial Organs (AREA)
Abstract
本发明涉及一种用于滤除白细胞的滤膜改性剂及其改性方法,所述滤膜改性剂由酰胺化修饰丝素蛋白、聚乙烯吡咯烷酮和丙烯酸酯共聚物以(0.05~2):(0.2~1):1的质量比组成。其中,丙烯酸酯共聚物由甲基丙烯酸甲酯单体和甲基丙烯酸二甲氨基乙酯单体构成。本发明所述的滤膜改性剂可溶于极性溶剂如水中配置成溶液,以浸润改性的方式对过滤膜进行涂覆处理,所述经滤膜改性剂处理后的过滤膜具有较好的润湿性、稳定性和相容性,对白细胞和血小板均具有较高的滤除率,且具有较低的改性剂洗出率,避免溶出物污染。
Description
技术领域
本发明属于白细胞过滤技术领域,具体涉及一种用于滤除白细胞的滤膜改性剂及其改性方法。
背景技术
输入含白细胞的全血或血液成分可引起非溶血性发热反应、人类白细胞抗原同种免疫、输血相关病毒感染和输血后移植物抗宿主病等输血不良反应,因此在输血前滤除血液制剂中的白细胞具有重要的意义。白细胞过滤器是滤除白细胞的重要方法,其原理是利用机械阻滞和吸附的原理截留白细胞,而让表面光滑、变形能力较强的红细胞通过。目前,第3代白细胞过滤器的要求是滤除率达到99.99%。
此外,研究表明血小板亦会诱导机体产生抗血小板抗体。抗血小板抗体是一种自身抗体,对自身的组织器官不识别,会攻击自身的组织器官,从而造成损害,因此,为了减少因输血小板而致的副作用,人们致力于研究一种在除去白细胞的同时也高效率地除去血小板的手段。以往有相关研究尝试通过减少过滤介质的纤维直径或孔径或增大过滤介质的填充密度作为提高过滤介质同时除去白细胞和血小板能力的手段。但是应用上述方法会存在这样的问题,即血液过滤处理时间延长和可能会导致红细胞膜破裂而出现溶血现象。
现有技术多采用表面接枝或涂覆亲水性聚合物对过滤材料表面进行改性,增加过滤材料的润湿性,降低过滤材料表面与血液的表面能,增加过滤材料接触血液的有效表面积,从而增加捕捉白细胞的机会。然而过滤材料表面的亲水性越高,血小板越难以活化,另外通过水和材料的氢键等可以很容易在材料表面形成水层,具有抑制血浆蛋白吸附,尤其是纤维蛋白的吸附,从而减少血小板的粘附性,对血小板的截留减少。此外,亲水性聚合物的水溶性较强,在血液中会存在溶出问题。
中国专利申请CN201180038373.2公开了用于从血液中或者从血液衍生物中除去物质的改进的过滤器以及用于获得所述过滤器的方法。所述的过滤器包含容纳层状的过滤器元件的壳体,所述层状的过滤器元件包含多个层,所述层状的过滤器元件的至少一层涂覆有聚氨酯,所述聚氨酯的分子量为12,000道尔顿至18,000道尔顿,并将涂覆有聚氨酯的非织造物夹杂在亲水性较小的织造物中形成的层状过滤元件,所述的层状过滤元件对白细胞和血小板均具有较好的滤除作用。
中国专利申请CN02816396.6公开了涂覆除白细胞的过滤器原材料用聚合物以及过滤器材料。所述的过滤器原材料为纤维状介质或海绵状构造物,并通过在过滤原材料的表面涂覆由来自疏水性聚合性单体的单元、来自含有碱性含氮部分的聚合性单体的单元和来自含有质子性中性亲水性部分的聚合性单体的单元构成的涂覆用聚合物,提高对白细胞和血小板的滤除率。
发明内容
为解决现有技术存在的问题,本发明的目的在于提供一种用于滤除白细胞的滤膜改性剂及其改性方法,所述的滤膜改性剂可溶于极性溶剂如水中配置成溶液,以浸润改性的方式对过滤膜进行涂覆处理,所述经改性剂处理后的过滤膜具有较好的润湿性、稳定性和相容性,对白细胞和血小板均具有较高的滤除率,且具有较低的改性剂洗出率,避免溶出物污染。
本发明通过如下技术方案以实现上述目的:
一种用于滤除白细胞的滤膜改性剂由酰胺化修饰丝素蛋白、聚乙烯吡咯烷酮和丙烯酸酯共聚物以(0.05~2):(0.2~1):1的质量比组成。
进一步地,所述滤膜改性剂由酰胺化修饰丝素蛋白、聚乙烯吡咯烷酮和丙烯酸酯共聚物以(0.4~1):(0.2~0.5):1的质量比组成。
优选地,所述滤膜改性剂由酰胺化修饰丝素蛋白、聚乙烯吡咯烷酮和丙烯酸酯共聚物以0.6:0.4:1的质量比组成。
进一步地,所述丙烯酸酯共聚物制备方法包括以下步骤:取等摩尔的甲基丙烯酸甲酯单体和甲基丙烯酸二甲氨基乙酯单体混合,置于反应器中,用氮气置换体系中的空气,加入其质量0.35~0.5%的引发剂,在氮气保护下,400W微波辐射4~5min,使其温度达到70℃,然后在150W微波辐射下反应6~10min,即得。
进一步地,所述引发剂为偶氮二异丁酸二甲酯。
进一步地,所述丙烯酸酯共聚物的聚合转化率为90~98%。
进一步地,所述酰胺化修饰丝素蛋白的制备方法包括以下步骤:将丝素蛋白溶于水,制成浓度为10mg/mL的溶液,以1:5的体积比加入1mol/L的尿素水溶液,混匀,然后用稀盐酸溶液调节pH值至4.75,然后加入丝素蛋白2倍重量的1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐,在室温下反应0.5~1h,在反应过程中适当滴入稀盐酸溶液,保持反应液的pH在4.75,反应结束后,加入pH为4.75的乙酸缓冲液,分解过量的1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐,然后将反应液在去离子水中进行透析,冷冻干燥,即得。
本发明所述的滤膜改性剂的制备方法包括以下步骤:取丙烯酸酯共聚物、聚乙烯吡咯烷酮混匀,加入水制成质量分数为5~10%的溶液,然后加入酰胺化修饰蛋白,置于低速搅拌器中,50℃下搅拌2~4h,即得改性剂水溶液。
本发明利用聚乙烯吡咯烷的分散和增溶作用,将其与丙烯酸酯共聚物混合,增加丙烯酸酯共聚物在水中的溶解性。
此外,本发明还提供一种使用所述滤除白细胞的滤膜改性剂进行滤膜改性的方法,包括以下步骤:将疏水性树脂纤维过滤膜置于改性剂水溶液中,20~40℃下浸渍0.5~2h,取出置于60℃下干燥20h,再用40℃水进行洗涤,60℃下继续烘干6h,即得。
所述的疏水性树脂纤维过滤膜为本领域常用的白细胞过滤膜,如聚对苯二甲酸乙二醇酯、聚对苯二甲酸丁二醇酯、聚对苯二甲酸丙二醇酯、聚-2,6-萘二酸乙二醇酯和聚对苯二甲酸三亚甲基二醇酯等材料制成的过滤膜。
优选地,所述疏水性树脂纤维过滤膜为聚对苯二甲酸丁二醇酯过滤膜。
本发明提供的酰胺化修饰丝素蛋白为丝素蛋白侧链羧基的酰胺化产物,通过改变自由羧基的数量,以达到改变丝素蛋白表面的荷电性,调节丝素蛋白的吸附性。所述的酰胺化修饰丝素蛋白与中性的血液相接触时,与带负电荷的血细胞之间的静电排斥力减小,促进对白细胞的吸附。此外,酰胺化修饰丝素蛋白具有类似胶原蛋白的性质,对血小板的吸附具有一定的促进作用。
聚乙烯吡咯烷酮分子中的酰胺结构具有强极性和形成氢键的能力,容易与酰胺化丝素蛋白、疏水性树脂纤维过过滤膜结构中的羟基、氨基等有机官能团结合,具有一定的固定作用,并可提高疏水性树脂纤维过过滤膜的亲水性。此外,其分子环上及长链中的亚甲基和次亚甲基具有一定的疏水性,其结构同时具有亲水亲油基团,使其带有表面活性,有利于降低疏水性树脂纤维过过滤膜的表面张力,提高白细胞和血小板的滤除效果。
本发明所述的丙烯酸共聚物由甲基丙烯酸甲酯单体和的甲基丙烯酸二甲氨基乙酯单体共聚合成,同时具有疏水部分和亲水部分,在水溶液中具有较好的分散性和溶解性,所述的丙烯酸共聚物结构中含有叔氨基,带有正电荷,有利于促进白细胞吸附。同时,其疏水性部分在一定程度上促进血小板活化,促进血小板粘附,使得血小板发挥吸附搭桥的作用,促进白细胞的捕捉,实现对白细胞和血小板的同时滤除。
另外,丙烯酸共聚物具有优良的粘合性,有利于增强改性剂在过滤膜表面的粘结力,从而提高涂层的稳定性。
与现有技术相比,本发明的优势在于:
(1)本发明提供的滤膜改性剂由酰胺化修饰丝素蛋白、聚乙烯吡咯烷酮和丙烯酸共聚物以一定的质量比组成,所述的滤膜改性剂各组分之间以及改性剂与滤膜之间均具有较好的相容性和交联性,经涂覆后的滤膜纤维表面光滑,使红细胞滤过过滤材料时不易受伤,同时显著提高对白细胞的滤除率,在一定程度上促进血小板活化,增强血小板的吸附搭桥能力,提高对白细胞和血小板的截留。
(2)本发明提供的滤膜改性剂具有较好的稳定性和结合力,以浸润改性的方式对滤膜进行涂覆处理,所述经滤膜改性剂处理后的滤膜具有较好的稳定性和较低的改性剂洗出率,避免洗出物污染。
具体实施方式
以下通过具体实施方式进一步描述本发明,但本发明不仅仅限于以下实施例。
实施例1丙烯酸酯共聚物的制备
组别 | 偶氮二异丁酸二甲酯用量(%) |
A | 0.35 |
B | 0.40 |
C | 0.45 |
D | 0.50 |
制备方法:
取等摩尔的甲基丙烯酸甲酯单体和甲基丙烯酸二甲氨基乙酯单体混合,置于反应器中,用氮气置换体系中的空气,加入其质量0.35~0.5%的偶氮二异丁酸二甲酯,在氮气保护下,400W微波辐射4min,使其温度达到70℃,然后在150W微波辐射下反应10min,即得。
将A-D组制得的丙烯酸酯共聚物进行聚合转化率测定,结果见下表:
组别 | 聚合转化率 |
A | 94% |
B | 96% |
C | 98% |
D | 95% |
由上表可知,当加入0.45%的偶氮二异丁酸二甲酯,制得的丙烯酸酯共聚物的聚合转化率最高,所得产物最纯。因此,以下实施例2、3、4和对比例1、2、3所述的滤膜改性剂均采用C组制得的丙烯酸酯共聚物进行制备。
实施例2滤膜改性剂制备
本发明实施例2的滤膜改性剂由酰胺化修饰丝素蛋白、聚乙烯吡咯烷酮和丙烯酸酯共聚物以0.6:0.4:1的质量比组成。
制备方法:
(1)酰胺化修饰丝素蛋白的制备:将丝素蛋白溶于水,制成浓度为10mg/mL的溶液,以1:5的体积比加入1mol/L的尿素水溶液,混匀,然后用稀盐酸溶液调节pH值至4.75,然后加入丝素蛋白2倍重量的1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐,在室温下反应0.5h,在反应过程中适当滴入稀盐酸溶液,保持反应液的pH在4.75,反应结束后,加入pH为4.75的乙酸缓冲液,分解过量的1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐,然后将反应液在去离子水中进行透析,冷冻干燥,即得酰胺化修饰丝素蛋白;
(2)滤膜改性制备:取丙烯酸酯共聚物、聚乙烯吡咯烷酮混匀,加入水制成质量分数为10%的溶液,然后加入酰胺化修饰蛋白,置于低速搅拌器中,50℃下搅拌3h,即得改性剂水溶液。
实施例3滤膜改性剂制备
本发明实施例3的滤膜改性剂由酰胺化修饰丝素蛋白、聚乙烯吡咯烷酮和丙烯酸酯共聚物以0.4:0.2:1的质量比组成。
制备方法同实施例2。
实施例4滤膜改性剂制备
本发明实施例4的滤膜改性剂由酰胺化修饰丝素蛋白、聚乙烯吡咯烷酮和丙烯酸酯共聚物以1:0.5:1的质量比组成。
制备方法同实施例2。
对比例1滤膜改性剂制备
本发明对比例1的滤膜改性剂由酰胺化修饰丝素蛋白、聚乙烯吡咯烷酮和丙烯酸酯共聚物以1:1:1的质量比组成。
制备方法参考实施例2,本对比例与实施例2的区别在于,所述滤膜改性剂由酰胺化修饰丝素蛋白、聚乙烯吡咯烷酮和丙烯酸酯共聚物以等质量比组成。
对比例2滤膜改性剂制备
本发明对比例2的滤膜改性剂由丝素蛋白、聚乙烯吡咯烷酮和丙烯酸酯共聚物以0.6:0.4:1的质量比组成。
制备方法参考实施例2,本对比例与实施例2的区别在于,所述过滤膜改性剂中的酰胺化修饰丝素蛋白改为丝素蛋白。
对比例3滤膜改性剂制备
本发明对比例3的滤膜改性剂由酰胺化修饰丝素蛋白和丙烯酸酯共聚物以1:1的质量比组成。
制备方法参考实施例2,本对比例与实施例2的区别在于,所述过滤膜改性剂不添加聚乙烯吡咯烷酮,并相应增加酰胺化修饰丝素蛋白的质量。
实施例5使用滤膜改性剂对白细胞过滤膜进行改性处理
分别使用本发明实施例2、3、4和对比例1、2、3制得的滤膜改性剂对聚对苯二甲酸丁二醇酯过滤膜进行改性处理,所述的改性方法包括以下步骤:将聚对苯二甲酸丁二醇酯过滤膜分别置于实施例2、3、4和对比例1、2、3制得的滤膜改性剂水溶液中,30℃下浸渍1h,取出置于60℃下干燥20h,再用40℃水进行洗涤,60℃下继续烘干6h,分别得到经实施例2、3、4和对比例1、2、3制得的滤膜改性剂进行改性处理的过滤膜。
试验例一、经本发明滤膜改性剂处理后的过滤膜的洗出率试验
分别对经本发明实施例2、3、4和对比例1、2、3制得的滤膜改性剂处理后的过滤膜在热水以及模拟实际应用过程的条件下进行洗出物试验,具体为:
(1)热水洗出率试验:
取经本发明改性剂处理后的聚对苯二甲酸丁二醇酯过滤膜于105℃烘箱中烘至恒重后,按1:100的浴比将样品在水浴恒温(37±1℃)振荡器中振荡溶解60min,然后滤出试样并放入105℃烘箱中烘至恒重。计算涂层的热水洗出率。涂层材料的热水洗出率(%)=(m1-m2)/m1×100,其中m1为试样水浴前的干质量(g),m2为试样水浴后的干质量(g)。
(2)模拟实际应用过程的洗出率试验:
取15g经本发明改性剂处理后的聚对苯二甲酸丁二醇酯过滤膜置于200ml的容器中,加入生理盐水溶液作为填充液,然后进行γ射线灭菌(照射线量25kGy)。为了在实际保管医疗用具时考虑的温度范围内确认洗出物,在25℃下保管24h后在4℃下保管24h。观察保存后填充液的外观,并使用紫外分光光度计测量在波长为220~350nm时填充液最大吸光度。
表1经本发明滤膜改性剂处理后的过滤膜的洗出率试验结果
由上试验可知,经本发明滤膜改性剂处理后的聚对苯二甲酸丁二醇酯过滤膜无论在热水条件下还是在模拟实际应用过程的条件下均具有较好的稳定性,洗出程度低。在热水条件下的洗出率为2.15%~2.51%,在模拟实际保管医疗用具时考虑的温度范围内,测得填充液的吸光度为0.042~0.050。由对比例1可知,当改性剂中各组分以等质量比组成,使改性剂在水(生理盐水溶液)中的洗出率增加,由对比例2可知,当改性剂中的酰胺化修饰丝素蛋白改为丝素蛋白,改性剂在水(生理盐水溶液)中的洗出率没有明显变化;由对比例3可知,当改性剂不添加聚乙烯吡咯烷酮,改性剂在水(生理盐水溶液)中的洗出率略增加,以上结果表明聚乙烯吡咯烷酮有助于增加改性剂在过滤膜表面的稳定性,而改性剂各组分以一定的质量比组成可在过滤膜表面形成较稳定的改性涂层。
试验例二、经本发明滤膜改性剂处理后的过滤膜的白细胞和血小板滤除效果评价
使用经本发明实施例2、3、4和对比例1、2、3制得的滤膜改性剂处理后的过滤膜对400ml全血进行在线过滤,评价本发明过滤膜除去白细胞和血小板的效果,采用血细胞计数仪测定过滤前、后全血中的白细胞和血小板数量,并记录全血过滤所需时间;测得400ml全血中过滤前白细胞的数量为2.5×109,过滤前血小板的数量为8×1010。
其中剩余白细胞数的测定方法为:将过滤后的全血采样至聚乙烯制的试管中,以吖啶橙液将漏出的白细胞染色后,用荧光显微镜进行测定。将测定的白细胞浓度乘以回收的全血的液量,测得回收袋中所含的剩余白细胞数。
白细胞(血小板)滤除率(%)=L0-L1/L0×100,其中L0为过滤前单位体积全血中含有的白细胞(血小板)数量,L1为过滤后单位体积全血中含有的白细胞(血小板)数量。
表2经本发明滤膜改性剂处理后的过滤膜对全血的过滤时间
由上表可知,经本发明实施例改性剂改性后过滤膜对400mL全血进行过滤只需要15~17min,而对比例1改性剂中的各组分以等质量比组成,过滤时间缩短,这可能与改性剂中亲水润湿性较强的酰胺化修饰丝素蛋白和聚乙烯吡咯烷酮的质量比重增加有关。经对比例2和对比例3改性剂改性后的过滤膜对全血的过滤时间增加,尤其以对比例3改性剂改性后的过滤膜对全血的过滤时间达29.8min,表明酰胺化修饰丝素蛋白较丝素蛋白有利于改善过滤膜的亲水润湿性,而聚乙烯吡咯烷酮的表面活性有助于全血通过过滤膜。
表3经本发明滤膜改性剂处理后的过滤膜对白细胞和血小板的滤除效果
由上表可知,经本发明实施例改性剂改性后过滤膜对全血中的白细胞和血小板均具有较好的滤除效率,其中对白细胞的滤除率高达99.999%,对血小板的滤除率达90%以上,均显著优于经对比例1-3改性剂改性后过滤膜对全血中的白细胞和血小板的滤除率,其滤除效果超过了第3代白细胞过滤器的要求。
以上仅是本发明的优选实施方式,应当指出的是,上述优选实施方式不应视为对本发明的限制,本发明的保护范围应当以权利要求所限定的范围为准。对于本技术领域的普通技术人员来说,在不脱离本发明的精神和范围内,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (10)
1.一种用于滤除白细胞的滤膜改性剂,其特征在于,所述滤膜改性剂由酰胺化修饰丝素蛋白、聚乙烯吡咯烷酮和丙烯酸酯共聚物以(0.05~2):(0.2~1):1的质量比组成。
2.根据权利要求1所述的滤除白细胞的滤膜改性剂,其特征在于,所述滤膜改性剂由酰胺化修饰丝素蛋白、聚乙烯吡咯烷酮和丙烯酸酯共聚物以(0.4~1):(0.2~0.5):1的质量比组成。
3.根据权利要求2所述的滤除白细胞的滤膜改性剂,其特征在于,所述滤膜改性剂由酰胺化修饰丝素蛋白、聚乙烯吡咯烷酮和丙烯酸酯共聚物以0.6:0.4:1的质量比组成。
4.根据权利要求1-3任一所述的滤除白细胞的滤膜改性剂,其特征在于,所述丙烯酸酯共聚物制备方法为:取等摩尔的甲基丙烯酸甲酯单体和甲基丙烯酸二甲氨基乙酯单体混合,置于反应器中,用氮气置换体系中的空气,加入其质量0.35~0.5%的引发剂,在氮气保护下,400W微波辐射4~5min,使其温度达到70℃,然后在150W微波辐射下反应6~10min,即得。
5.根据权利要求4所述的滤除白细胞的滤膜改性剂,其特征在于,所述引发剂为偶氮二异丁酸二甲酯。
6.根据权利要求4所述的滤除白细胞的滤膜改性剂,其特征在于,所述丙烯酸酯共聚物的聚合转化率为90~98%。
7.根据权利要求1-3任一所述的滤除白细胞的滤膜改性剂,其特征在于,所述酰胺化修饰丝素蛋白的制备方法为:将丝素蛋白溶于水,制成浓度为10mg/mL的溶液,以1:5的体积比加入1mol/L的尿素水溶液,混匀,然后用稀盐酸溶液调节pH值至4.75,然后加入丝素蛋白2倍重量的1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐,在室温下反应0.5~1h,在反应过程中适当滴入稀盐酸溶液,保持反应液的pH在4.75,反应结束后,加入pH为4.75的乙酸缓冲液,分解过量的1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐,然后将反应液在去离子水中进行透析,冷冻干燥,即得。
8.根据权利要求1-7任一所述的滤除白细胞的滤膜改性剂的制备方法,其特征在于,包括以下步骤:取丙烯酸酯共聚物、聚乙烯吡咯烷酮混匀,加入水制成质量分数为5~10%的溶液,然后加入酰胺化修饰蛋白,置于低速搅拌器中,50℃下搅拌2~4h,即得改性剂水溶液。
9.一种使用如权利要求1-7任一所述的滤除白细胞的滤膜改性剂进行滤膜改性的方法,其特征在于,包括以下步骤:将疏水性树脂纤维过滤膜置于改性剂水溶液中,20~40℃下浸渍0.5~2h,取出置于60℃下干燥20h,再用40℃水进行洗涤,60℃下继续烘干6h,即得。
10.根据权利要求9所述的使用滤除白细胞的滤膜改性剂进行滤膜改性的方法,其特征在于,所述疏水性树脂纤维过滤膜为聚对苯二甲酸丁二醇酯过滤膜。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610471055.XA CN106117580A (zh) | 2016-06-23 | 2016-06-23 | 一种用于滤除白细胞的滤膜改性剂及其改性方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610471055.XA CN106117580A (zh) | 2016-06-23 | 2016-06-23 | 一种用于滤除白细胞的滤膜改性剂及其改性方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106117580A true CN106117580A (zh) | 2016-11-16 |
Family
ID=57268819
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610471055.XA Withdrawn CN106117580A (zh) | 2016-06-23 | 2016-06-23 | 一种用于滤除白细胞的滤膜改性剂及其改性方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106117580A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US12031128B2 (en) | 2021-04-07 | 2024-07-09 | Battelle Memorial Institute | Rapid design, build, test, and learn technologies for identifying and using non-viral carriers |
US12109223B2 (en) | 2020-12-03 | 2024-10-08 | Battelle Memorial Institute | Polymer nanoparticle and DNA nanostructure compositions and methods for non-viral delivery |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5547576A (en) * | 1992-07-06 | 1996-08-20 | Terumo Kabushiki Kaisha | Pathogenic substance removing material and a blood filter containing the material |
CN1268893A (zh) * | 1997-08-28 | 2000-10-04 | 旭医学株式会社 | 除白细胞的过滤介质 |
CN1741839A (zh) * | 2003-01-24 | 2006-03-01 | 弗雷泽纽斯血液保健意大利有限公司 | 从全血或血液制剂中分离白细胞的过滤器,该过滤器的生产方法,相应的设备及其用途 |
CN1856332A (zh) * | 2003-09-23 | 2006-11-01 | 弗雷森纽斯血液护理意大利有限公司 | 从血液产品中去除物质的过滤器 |
CN104923091A (zh) * | 2014-03-20 | 2015-09-23 | 上海世龙科技有限公司 | 白细胞过滤膜、其制造方法和用途 |
-
2016
- 2016-06-23 CN CN201610471055.XA patent/CN106117580A/zh not_active Withdrawn
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5547576A (en) * | 1992-07-06 | 1996-08-20 | Terumo Kabushiki Kaisha | Pathogenic substance removing material and a blood filter containing the material |
CN1268893A (zh) * | 1997-08-28 | 2000-10-04 | 旭医学株式会社 | 除白细胞的过滤介质 |
CN1741839A (zh) * | 2003-01-24 | 2006-03-01 | 弗雷泽纽斯血液保健意大利有限公司 | 从全血或血液制剂中分离白细胞的过滤器,该过滤器的生产方法,相应的设备及其用途 |
CN1856332A (zh) * | 2003-09-23 | 2006-11-01 | 弗雷森纽斯血液护理意大利有限公司 | 从血液产品中去除物质的过滤器 |
CN104923091A (zh) * | 2014-03-20 | 2015-09-23 | 上海世龙科技有限公司 | 白细胞过滤膜、其制造方法和用途 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US12109223B2 (en) | 2020-12-03 | 2024-10-08 | Battelle Memorial Institute | Polymer nanoparticle and DNA nanostructure compositions and methods for non-viral delivery |
US12031128B2 (en) | 2021-04-07 | 2024-07-09 | Battelle Memorial Institute | Rapid design, build, test, and learn technologies for identifying and using non-viral carriers |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100349934C (zh) | 生物相容性聚合物和使用它的白细胞选择除去过滤材料 | |
Yue et al. | Grafting of zwitterion from polysulfone membrane via surface-initiated ATRP with enhanced antifouling property and biocompatibility | |
EP1473310B1 (en) | Leukocyte removal filter comprising a polymer coating | |
CN104902941B (zh) | 血液净化柱 | |
CN101663057B (zh) | 中空纤维膜式人工肺 | |
RU2749419C2 (ru) | Материал для очистки крови | |
CN107406551A (zh) | 共聚物以及使用其的医疗设备、医疗用分离膜模块和血液净化器 | |
Zheng et al. | In vitro hemocompatibility and hemodialysis performance of hydrophilic ionic liquid grafted polyethersulfone hollow fiber membranes | |
Qin et al. | Insights into the surface property and blood compatibility of polyethersulfone/polyvinylpyrrolidone composite membranes: toward high‐performance hemodialyzer | |
CN107057095A (zh) | 一种交联的复合聚乙烯醇材料 | |
JP4251987B2 (ja) | 白血球選択除去フィルター材 | |
CN106117580A (zh) | 一种用于滤除白细胞的滤膜改性剂及其改性方法 | |
US20030146150A1 (en) | Novel leukapheretic filter | |
CN106139935A (zh) | 一种白细胞和血小板的过滤膜及其制备方法 | |
CN105903270A (zh) | 一种高效滤除白细胞和血小板的过滤材料及其制备方法 | |
CN106117590A (zh) | 一种白细胞过滤膜的改性方法 | |
CN104923091B (zh) | 白细胞过滤膜、其制造方法和用途 | |
Gérard et al. | Surface modification of polypropylene nonwovens with LDV peptidomimetics and their application in the leukodepletion of blood products | |
CN110787647B (zh) | 一种血小板去白细胞过滤膜及其制备方法 | |
Radhakumary et al. | Chitosan‐comb‐graft‐polyethylene glycol monomethacrylate—Synthesis, characterization, and evaluation as a biomaterial for hemodialysis applications | |
Zhang et al. | Preparation of anticoagulant polyvinylidene fluoride hollow fiber hemodialysis membranes | |
JPS60240725A (ja) | 抗血栓性医療材料 | |
JP2021145918A (ja) | 活性化顆粒球−活性化血小板複合体の除去材料 | |
JP2004129941A (ja) | 白血球選択除去フィルター | |
CN115245709B (zh) | 一种选择性去除白细胞同时保留血小板的滤材及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20161116 |